BioNTech AG is a fully integrated biotech company which combines all building blocks of immunotherapies under one roof. Through its diversified technology platforms and in-house diagnostics and manufacturing units BioNTech is strategically very well positioned to implement its lab-bench-to-market strategy.
BioNTech is pioneering disruptive technologies ranging from individualized mRNA based medicines through innovative Chimeric Antigen Receptors and T-cell Receptor-based products and novel antibody checkpoint immunomodulators.
Founded in 2008 as a spin-off of the prestigious Johannes-Gutenberg University in Mainz, BioNTech has grown rapidly to 400 employees with the majority of these engaged in the laboratories. Our research headquarters are based in Mainz, Germany.
BioNTech is privately held and shareholders include the MIG Fonds and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder.